Undisclosed IRF5 inhibitor / AbbVie, HotSpot Therap - LARVOL DELTA

HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025 (PRNewswire) - "HotSpot Therapeutics, Inc....today announced it will present preclinical data from the Company's interferon regulatory factor 5 (IRF5) program in an oral and poster presentation at the 25th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2025), taking place June 24-27, 2025, in Boston, MA."

Preclinical • Immunology